Pulmonary Hypertension Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Embolism
Conditions: Chronic Thromboembolic Pulmonary Hypertension Sponsors: Ester Ashraf Faried Beshay Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 13, 2023 Category: Research Source Type: clinical trials
Hemodynamic Effect of Nasal High-flow in Patients Suspected or Followed for a Precapillary Pulmonary Hypertension
Conditions: Pulmonary Hypertension Interventions: Device: Nasal high-flow Sponsors: ADIR Association Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 12, 2023 Category: Research Source Type: clinical trials
HA Residents With PVD, SDB Assessed at HA (2840m) vs LA (Sea Level)
Conditions: Pulmonary Vascular Disease; Pulmonary Artery Hypertension; Chronic Thromboembolic Pulmonary Hypertension Interventions: Other: Assessment without intervention at High altitude; Other: Relocation to sea level for 2 days Sponsors: University of Zurich Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 9, 2023 Category: Research Source Type: clinical trials
Impact of Pulmonary Endarterectomy on Sleep-Related Breathing Disorders
Conditions: Sleep-Disordered Breathing; Chronic Thromboembolic Pulmonary Hypertension; Post Operative Interventions: Procedure: Pulmonary endarterectomy Sponsors: Marmara University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials
Impact of Pulmonary Endarterectomy on Sleep-Related Breathing Disorders in CTEPH: The IPES Trial
Conditions: Sleep-Disordered Breathing; Chronic Thromboembolic Pulmonary Hypertension; Post Operative Interventions: Procedure: Pulmonary endarterectomy Sponsors: Marmara University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials
Repurposing Valsartan May Protect Against Pulmonary Hypertension
Conditions: Pulmonary Arterial Hypertension; Right Heart Failure; Right Ventricular Dysfunction; Pulmonary Vascular Disorder Interventions: Drug: Valsartan 40 mg; Drug: Placebo Sponsors: University of Washington; National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials
Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 Study)
Conditions: Group 2 Pulmonary Hypertension; Heart Failure Intervention: Device: Gradient Denervation System Sponsor: Gradient Denervation Technologies Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials
Repurposing Valsartan May Protect Against Pulmonary Hypertension
Conditions: Pulmonary Arterial Hypertension; Right Heart Failure; Right Ventricular Dysfunction; Pulmonary Vascular Disorder Interventions: Drug: Valsartan 40 mg; Drug: Placebo Sponsors: University of Washington; National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials
Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 Study)
Conditions: Group 2 Pulmonary Hypertension; Heart Failure Intervention: Device: Gradient Denervation System Sponsor: Gradient Denervation Technologies Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials
Repurposing Valsartan May Protect Against Pulmonary Hypertension
Conditions: Pulmonary Arterial Hypertension; Right Heart Failure; Right Ventricular Dysfunction; Pulmonary Vascular Disorder Interventions: Drug: Valsartan 40 mg; Drug: Placebo Sponsors: University of Washington; National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials
Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 Study)
Conditions: Group 2 Pulmonary Hypertension; Heart Failure Intervention: Device: Gradient Denervation System Sponsor: Gradient Denervation Technologies Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials
Repurposing Valsartan May Protect Against Pulmonary Hypertension
Conditions: Pulmonary Arterial Hypertension; Right Heart Failure; Right Ventricular Dysfunction; Pulmonary Vascular Disorder Interventions: Drug: Valsartan 40 mg; Drug: Placebo Sponsors: University of Washington; National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials
Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 Study)
Conditions: Group 2 Pulmonary Hypertension; Heart Failure Intervention: Device: Gradient Denervation System Sponsor: Gradient Denervation Technologies Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials
Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 Study)
Conditions: Group 2 Pulmonary Hypertension; Heart Failure Interventions: Device: Gradient Denervation System Sponsors: Gradient Denervation Technologies Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials
Repurposing Valsartan May Protect Against Pulmonary Hypertension
Conditions: Pulmonary Arterial Hypertension; Right Heart Failure; Right Ventricular Dysfunction; Pulmonary Vascular Disorder Interventions: Drug: Valsartan 40 mg; Drug: Placebo Sponsors: University of Washington; National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials